Loading
474 approved and phase-3 products compared across 7 regulators. 6 are approved in all 7 regions, 51 are approved in the US but not the EU, and 51 are approved only in China. Filter by gap type to see where a pipeline exists in one region and is missing in another.
| Radioactive iodine (I-131) · Sodium iodide I-131 | Radiopharmaceutical (beta/gamma emitter, natural uptake) | 1951 | 1990 | 1990 | 1990 | 1990 | 1990 | · | 6/7 | 1951 US |
| Methotrexate · Trexall / Otrexup / Xatmep | Antifolate (DHFR inhibitor) | 1953 | · | 6/7 | 1953 US | |||||
| Cyclophosphamide · Cytoxan / Endoxan | Alkylating agent (oxazaphosphorine prodrug) | 1959 | · | 6/7 | 1959 US | |||||
| Fluorouracil (5-FU) · Adrucil / Efudex | Fluoropyrimidine antimetabolite | 1962 | · | 6/7 | 1962 US | |||||
| Vincristine · Oncovin / Marqibo | Vinca alkaloid (microtubule inhibitor) | 1963 | · | 6/7 | 1963 US | |||||
| Dactinomycin (actinomycin D) · Cosmegen | Actinomycin antibiotic (transcription inhibitor) | 1964 | · | 6/7 | 1964 US | |||||
| Melphalan (including hepatic delivery system) · Alkeran / Evomela / Hepzato Kit | Alkylating agent (nitrogen mustard) | 1964 | · | 6/7 | 1964 US | |||||
| Vinblastine · Velban | Vinca alkaloid (microtubule inhibitor) | 1965 | · | 6/7 | 1965 US | |||||
| Hydroxyurea (hydroxycarbamide) · Hydrea / Droxia / Siklos | Oral ribonucleotide reductase inhibitor (cytoreductive) | 1967 | · | 6/7 | 1967 US | |||||
| Cytarabine + anthracycline ('7+3') | Cytotoxic regimen | 1969 | · | · | · | · | 3/7 | 1969 US | ||
| Mitotane · Lysodren | Adrenolytic agent (DDD derivative) | 1970 | 2004 | 2004 | · | · | · | 4/7 | 1970 US | |
| Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD) · Megace; Mirena (IUD) | Hormonal therapy (progestin) | 1971 | 1970 | 1970 | 1980 | 1995 | 1975 | · | 6/7 | 1970 EU/UK |
| Doxorubicin · Adriamycin | Cytotoxic chemotherapy (anthracycline) | 1974 | 1971 | 1971 | 1975 | 1980 | 1975 | · | 6/7 | 1971 EU/UK |
| Bleomycin · Blenoxane | Glycopeptide antibiotic (DNA-cleaving) | 1973 | · | 6/7 | 1973 US | |||||
| Tamoxifen · Nolvadex | Small-molecule SERM | 1977 | 1973 | 1973 | 1981 | 1990 | 1976 | · | 6/7 | 1973 EU/UK |
| Mitomycin C · Mutamycin / Jelmyto / Zusduri | Alkylating antibiotic (bioreductive) | 1974 | · | 6/7 | 1974 US | |||||
| Lomustine (CCNU) · Gleostine | Oral nitrosourea chemotherapy | 1976 | · | · | · | · | · | 2/7 | 1976 US | |
| Cisplatin · Platinol (generic) | Cytotoxic chemotherapy (platinum) | 1978 | 1979 | 1979 | 1983 | 1985 | 1980 | · | 6/7 | 1978 US |
| Ifosfamide · Ifex | Cytotoxic chemotherapy (alkylating agent) | 1988 | 1980 | 1980 | 1985 | 1990 | 1985 | · | 6/7 | 1980 EU/UK |
| Etoposide · VePesid / Etopophos / Toposar | Topoisomerase II inhibitor (podophyllotoxin derivative) | 1983 | · | 6/7 | 1983 US | |||||
| Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi | GnRH agonist depot | 1985 | · | 6/7 | 1985 US | |||||
| Carboplatin | Cytotoxic chemotherapy (platinum) | 1989 | 1986 | 1986 | 1990 | 1990 | 1988 | · | 6/7 | 1986 EU/UK |
| Goserelin / leuprolide (ovarian function suppression) · Zoladex; Lupron | GnRH agonist | 1989 | 1987 | 1987 | 1991 | 1996 | 1990 | · | 6/7 | 1987 EU/UK |
| Somatostatin analogues (octreotide, lanreotide) · Sandostatin LAR, Somatuline Depot | Peptide hormone analogue (SSTR2 agonist) | 1988 | 1988 | 1988 | 1991 | 1996 | 1990 | · | 6/7 | 1988 US/EU/UK |
| Vinorelbine · Navelbine | Semi-synthetic vinca alkaloid | 1994 | 1989 | · | 6/7 | 1989 EU | ||||
| Intravesical BCG · TICE BCG | Live bacterial immunotherapy (intravesical) | 1990 | · | · | · | · | 3/7 | 1990 US | ||
| Aldesleukin (high-dose IL-2) · Proleukin | Recombinant interleukin-2 (cytokine) | 1992 | · | · | · | 4/7 | 1992 US | |||
| Paclitaxel / nab-paclitaxel · Taxol / Abraxane | Cytotoxic chemotherapy (taxane) | 1992 | 1993 | 1993 | 1997 | 1995 | 1994 | · | 6/7 | 1992 US |
| Cladribine · Leustatin / Litak | Purine nucleoside analogue | 1993 | 2004 | · | · | 5/7 | 1993 US | |||
| Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) · Oncaspar / Asparlas / Rylaze / Erwinaze | Enzyme therapy | 1994 | 2016 | · | 6/7 | 1994 US | ||||
| Irinotecan (and liposomal irinotecan) · Camptosar / Onivyde | Topoisomerase I inhibitor (camptothecin prodrug) | 1996 | 1994 | · | 6/7 | 1994 JP | ||||
| Bicalutamide · Casodex | Oral first-generation non-steroidal antiandrogen | 1995 | 1995 | 1995 | 1999 | · | 6/7 | 1995 US/EU/UK | ||
| Docetaxel · Taxotere (generic) | Cytotoxic chemotherapy (taxane) | 1996 | 1995 | 1995 | 1996 | 1996 | 1996 | · | 6/7 | 1995 EU/UK |
| Pegylated liposomal doxorubicin · Doxil / Caelyx | Cytotoxic (liposomal anthracycline) | 1995 | 1996 | 1996 | 2007 | 2003 | 1997 | · | 6/7 | 1995 US |
| Tretinoin (all-trans retinoic acid, ATRA) · Vesanoid | Oral retinoid (differentiation agent) | 1995 | · | 6/7 | 1995 US | |||||
| Gemcitabine · Gemzar / Infugem | Nucleoside analogue (deoxycytidine) | 1996 | 1999 | · | 6/7 | 1996 US | ||||
| Ibandronic acid · Bondronat | Nitrogen-containing bisphosphonate (intravenous and oral) | · | 1996 | · | · | · | · | · | 1/7 | 1996 EU |
| Letrozole (and other aromatase inhibitors) · Femara; anastrozole (Arimidex); exemestane (Aromasin) | Small-molecule aromatase inhibitor | 1997 | 1996 | 1996 | 2006 | 2000 | 1997 | · | 6/7 | 1996 EU/UK |
| Oxaliplatin · Eloxatin | Third-generation platinum (DACH-platinum) | 2002 | 1996 | 2005 | · | 6/7 | 1996 EU | |||
| Topotecan · Hycamtin | Cytotoxic (topoisomerase-I inhibitor) | 1996 | 1996 | 1996 | 2000 | 2000 | 1998 | · | 6/7 | 1996 US/EU/UK |
| Toremifene · Fareston | Selective oestrogen receptor modulator (triphenylethylene) | · | 1996 | · | · | · | · | · | 1/7 | 1996 EU |
| Rituximab · Rituxan / MabThera (and biosimilars) | Monoclonal antibody (anti-CD20, chimeric) | 1997 | 1998 | 1998 | 2001 | 2000 | 1998 | 7/7 | 1997 US | |
| Imiquimod · Aldara / Zyclara | Topical immune response modifier (TLR7 agonist) | · | 1998 | · | · | · | · | · | 1/7 | 1998 EU |
| Samarium-153 lexidronam · Quadramet | Bone-seeking therapeutic radiopharmaceutical (beta emitter) | · | 1998 | · | · | · | · | · | 1/7 | 1998 EU |
| Thalidomide · Thalomid | Oral cereblon modulator (first IMiD) | 1998 | 2008 | 2008 | 2008 | · | · | 5/7 | 1998 US | |
| Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab) | Monoclonal antibody (anti-HER2) | 1998 | 2000 | 2000 | 2001 | 2002 | 2000 | 7/7 | 1998 US | |
| Alitretinoin · Panretin | Topical retinoid gel | 1999 | 2021 | · | · | · | · | · | 1/7 | 1999 US |
| Exemestane · Aromasin | Small-molecule steroidal aromatase inactivator | 1999 | 1999 | 1999 | 2002 | 2001 | 2000 | · | 6/7 | 1999 US/EU/UK |
| Tasonermin · Beromun | Recombinant tumour necrosis factor alpha for isolated limb perfusion | · | 1999 | · | · | · | · | · | 1/7 | 1999 EU |
| Temozolomide · Temodar | Oral alkylating chemotherapy | 1999 | 1999 | 1999 | 2006 | · | · | · | 4/7 | 1999 US/EU/UK |
| Arsenic trioxide · Trisenox | Inorganic arsenical (differentiation agent) | 2000 | 2002 | 2002 | 2004 | · | 6/7 | 2000 US | ||
| Gemtuzumab ozogamicin · Mylotarg | ADC | 2000 | 2018 | 2018 | 2005 | · | 2020 | · | 5/7 | 2000 US |
| Thyrotropin alfa · Thyrogen | Recombinant human thyroid-stimulating hormone | · | 2000 | · | · | · | · | · | 1/7 | 2000 EU |
| Bexarotene · Targretin | Small-molecule retinoid X receptor agonist | · | 2001 | · | · | · | · | · | 1/7 | 2001 EU |
| Capecitabine · Xeloda | Oral fluoropyrimidine prodrug (antimetabolite) | · | 2001 | · | · | · | · | · | 1/7 | 2001 EU |
| Darbepoetin alfa · Aranesp | Hyperglycosylated recombinant erythropoietin (erythropoiesis-stimulating agent) | · | 2001 | · | · | · | · | · | 1/7 | 2001 EU |
| Imatinib · Gleevec | Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA) | 2001 | 2001 | 2001 | 2001 | 2002 | 2001 | 7/7 | 2001 US/EU/UK/JP/AU | |
| Rasburicase · Elitek | Recombinant enzyme (urate oxidase) | · | 2001 | · | · | · | · | · | 1/7 | 2001 EU |
| Temoporfin · Foscan | Intravenous photosensitiser for photodynamic therapy | · | 2001 | · | · | · | · | · | 1/7 | 2001 EU |
| Zoledronic acid · Zometa | Nitrogen-containing bisphosphonate (intravenous) | · | 2001 | · | · | · | · | · | 1/7 | 2001 EU |
| Fulvestrant · Faslodex | Injectable SERD | 2002 | 2004 | 2004 | 2011 | 2010 | 2004 | · | 6/7 | 2002 US |
| Gefitinib · Iressa | Small-molecule EGFR TKI (first generation, reversible) | 2003 | 2009 | 2009 | 2002 | 2005 | · | 6/7 | 2002 JP | |
| Pegfilgrastim · Neulasta | Pegylated recombinant granulocyte colony-stimulating factor | · | 2002 | · | · | · | · | · | 1/7 | 2002 EU |
| Aprepitant (and fosaprepitant) · Emend / Cinvanti | Neurokinin-1 receptor antagonist (antiemetic) | · | 2003 | · | · | · | · | · | 1/7 | 2003 EU |
| Bortezomib · Velcade | Proteasome inhibitor | 2003 | 2004 | 2004 | 2006 | 2005 | 2005 | · | 6/7 | 2003 US |
| Anagrelide · Agrylin / Xagrid | Oral platelet-lowering agent (imidazoquinazoline) | · | 2004 | · | · | · | · | · | 1/7 | 2004 EU |
| Azacitidine · Vidaza / Onureg (oral) | Small-molecule hypomethylating agent (cytotoxic) | 2004 | 2008 | 2008 | 2011 | 2017 | 2009 | · | 6/7 | 2004 US |
| Bevacizumab · Avastin (and biosimilars) | Monoclonal antibody (anti-VEGF) | 2004 | 2005 | 2005 | 2007 | 2010 | 2005 | 7/7 | 2004 US | |
| Cetuximab · Erbitux | Monoclonal antibody (anti-EGFR) | 2004 | 2004 | 2004 | 2008 | 2006 | 2005 | · | 6/7 | 2004 US/EU/UK |
| Erlotinib · Tarceva | Small-molecule EGFR TKI (first generation, reversible) | 2004 | 2005 | 2005 | 2007 | · | 6/7 | 2004 US | ||
| Pemetrexed · Alimta (and generics) | Cytotoxic (antifolate) | 2004 | 2004 | 2004 | 2007 | 2005 | 2004 | · | 6/7 | 2004 US/EU/UK/AU |
| H101 oncolytic adenovirus | Oncolytic virus (E1B-deleted adenovirus) | · | · | · | · | 2005 | · | · | 1/7 | 2005 CN |
| Lenalidomide · Revlimid | Immunomodulatory drug (cereblon E3 ligase modulator) | 2005 | 2007 | 2007 | 2010 | 2013 | 2007 | · | 6/7 | 2005 US |
| Palonosetron · Aloxi | Second-generation 5-HT3 receptor antagonist (antiemetic) | · | 2005 | · | · | · | · | · | 1/7 | 2005 EU |
| Recombinant human endostatin | Recombinant angiogenesis inhibitor protein | · | · | · | · | 2005 | · | · | 1/7 | 2005 CN |
| Sorafenib · Nexavar | Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF) | 2005 | 2006 | 2006 | 2008 | 2006 | 2006 | 7/7 | 2005 US | |
| Clofarabine · Clolar | Purine nucleoside analogue (antimetabolite) | · | 2006 | · | · | · | · | · | 1/7 | 2006 EU |
| Dasatinib · Sprycel | Small-molecule kinase inhibitor (BCR::ABL1, SRC) | 2006 | 2006 | 2006 | 2009 | 2011 | 2007 | · | 6/7 | 2006 US/EU/UK |
| HPV quadrivalent vaccine (types 6, 11, 16 and 18) · Gardasil | Recombinant virus-like particle vaccine | · | 2006 | · | · | · | · | · | 1/7 | 2006 EU |
| Human normal immunoglobulin (IVIg) · Privigen / Kiovig | Pooled human polyclonal IgG antibody preparation (intravenous immunoglobulin) | · | 2006● | · | · | · | · | · | 1/7 | 2006 EU |
| Panitumumab · Vectibix | Monoclonal antibody (anti-EGFR) | 2006 | 2007 | 2007 | 2010 | 2021 | 2008 | · | 6/7 | 2006 US |
| Sunitinib · Sutent | Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT) | 2006 | 2006 | 2006 | 2008 | 2007 | 2006 | · | 6/7 | 2006 US/EU/UK/AU |
| 5-Aminolevulinic acid (oral, for glioma surgery) · Gleolan / Gliolan | Fluorescence-guided surgery agent (protoporphyrin IX precursor) | 2017 | 2007 | 2007 | 2013 | · | · | 5/7 | 2007 EU/UK | |
| Epoetin alfa · Epogen / Procrit | Recombinant erythropoietin (erythropoiesis-stimulating agent) | · | 2007 | · | · | · | · | · | 1/7 | 2007 EU |
| HPV bivalent vaccine (types 16 and 18) · Cervarix | Recombinant virus-like particle vaccine (adjuvanted) | · | 2007 | · | · | · | · | · | 1/7 | 2007 EU |
| Lapatinib · Tykerb | Small-molecule reversible HER2/EGFR kinase inhibitor | 2007 | 2008 | 2008 | 2009 | 2013 | 2007 | · | 6/7 | 2007 US/AU |
| Nelarabine · Arranon | Purine nucleoside prodrug (antimetabolite) | · | 2007 | · | · | · | · | · | 1/7 | 2007 EU |
| Nilotinib · Tasigna | Small-molecule BCR-ABL1 TKI (second generation) | 2007 | 2007 | 2007 | 2009 | 2009 | · | 6/7 | 2007 US/EU/UK | |
| Temsirolimus · Torisel | Intravenous mTOR inhibitor (rapamycin analogue) | 2007 | 2007 | 2007 | 2010 | · | · | · | 4/7 | 2007 US/EU/UK |
| Trabectedin · Yondelis | Cytotoxic (DNA minor-groove binder) | 2015 | 2007 | 2007 | 2015 | · | 2010 | · | 5/7 | 2007 EU/UK |
| Bendamustine · Treanda / Bendeka / Belrapzo | Alkylating agent (nitrogen mustard-purine hybrid) | 2008 | 2010 | 2010 | 2010 | · | · | · | 4/7 | 2008 US |
| Degarelix · Firmagon | GnRH antagonist depot | 2008 | 2009 | 2009 | 2012 | 2018 | · | 6/7 | 2008 US | |
| Fentanyl (transmucosal, for breakthrough cancer pain) · Effentora / Instanyl / PecFent | Small-molecule opioid analgesic (buccal tablet and nasal sprays) | · | 2008● | · | · | · | · | · | 1/7 | 2008 EU |
| Histamine dihydrochloride · Ceplene | Immunomodulator (H2 receptor agonist) given with interleukin-2 | · | 2008 | · | · | · | · | · | 1/7 | 2008 EU |
| Bevacizumab (glioblastoma use) · Avastin | Monoclonal antibody (anti-VEGF) | 2009 | · | 2013 | · | 2010 | · | 3/7 | 2009 US | |
| Epoetin theta · Eporatio / Biopoin | Recombinant erythropoietin (erythropoiesis-stimulating agent) | · | 2009● | · | · | · | · | · | 1/7 | 2009 EU |
| Everolimus · Afinitor | Small-molecule mTOR inhibitor | 2009 | 2009 | 2009 | 2010 | 2013 | 2009 | · | 6/7 | 2009 US/EU/UK/AU |
| Mifamurtide · Mepact | Liposomal muramyl tripeptide (macrophage activator) | 2007 | 2009 | 2009 | · | · | · | · | 2/7 | 2009 EU/UK |
| Pazopanib · Votrient | Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT) | 2009 | 2010 | 2010 | 2012 | 2017 | 2010 | · | 6/7 | 2009 US |
| Plerixafor · Mozobil | Small-molecule CXCR4 antagonist (stem cell mobiliser) | · | 2009 | · | · | · | · | · | 1/7 | 2009 EU |
| Pralatrexate · Folotyn | Antifolate (DHFR inhibitor) | 2009 | 2012 | · | 2017 | · | · | · | 2/7 | 2009 US |
| Romidepsin · Istodax | Class I HDAC inhibitor (cyclic peptide) | 2009 | · | 2017 | · | · | · | 2/7 | 2009 US | |
| Vinflunine · Javlor | Fluorinated vinca alkaloid (microtubule inhibitor) | · | 2009 | · | · | · | · | · | 1/7 | 2009 EU |
| Cabazitaxel · Jevtana | Cytotoxic chemotherapy (taxane) | 2010 | 2011 | 2011 | 2014 | 2020 | 2011 | · | 6/7 | 2010 US |
| Denosumab · Xgeva / Prolia | Monoclonal antibody (anti-RANKL, fully human IgG2) | · | 2010 | · | · | · | · | · | 1/7 | 2010 EU |
| Eribulin · Halaven | Synthetic halichondrin B analogue (microtubule dynamics inhibitor) | 2010 | 2011 | 2011 | 2011 | 2019 | · | 6/7 | 2010 US | |
| Sipuleucel-T · Provenge | Autologous cellular immunotherapy (antigen-presenting cell vaccine) | 2010 | 2015 | · | · | · | · | · | 1/7 | 2010 US |
| Thiotepa · Tepadina | Alkylating agent (ethylenimine) | · | 2010 | · | · | · | · | · | 1/7 | 2010 EU |
| Abiraterone acetate · Zytiga (generic) | Small-molecule CYP17A1 inhibitor | 2011 | 2011 | 2011 | 2014 | 2015 | 2012 | 7/7 | 2011 US/EU/UK | |
| Brentuximab vedotin · Adcetris | ADC | 2011 | 2012 | 2012 | 2014 | 2020 | 2013 | · | 6/7 | 2011 US |
| Crizotinib · Xalkori | Small-molecule ALK/ROS1/MET TKI (first generation) | 2011 | 2012 | 2012 | 2012 | 2013 | · | 6/7 | 2011 US | |
| Icotinib · Conmana | Small-molecule first-generation EGFR TKI | · | · | · | 2011 | · | · | 1/7 | 2011 CN | |
| Ipilimumab · Yervoy | Monoclonal antibody (anti-CTLA-4) | 2011 | 2011 | 2011 | 2015 | 2021 | 2011 | · | 6/7 | 2011 US/EU/UK/AU |
| Optune / Optune Pax (TTFields) · Optune | Device (tumour treating fields) | 2011 | 2015 | · | 2016 | 2020 | · | · | 4/7 | 2011 US |
| Ruxolitinib · Jakafi / Jakavi | Small-molecule JAK1/JAK2 inhibitor | 2011 | 2012 | 2012 | 2014 | 2017 | · | 6/7 | 2011 US | |
| Tegafur, gimeracil and oteracil (S-1) · Teysuno | Oral fluoropyrimidine combination (antimetabolite) | · | 2011 | · | · | · | · | · | 1/7 | 2011 EU |
| Vandetanib · Caprelsa | Small-molecule kinase inhibitor (RET, VEGFR, EGFR) | 2011 | 2012 | 2012 | 2015 | · | 2013 | · | 5/7 | 2011 US |
| Vemurafenib · Zelboraf | Small-molecule kinase inhibitor (BRAF V600) | 2011 | 2012 | 2012 | 2014 | 2017 | 2012 | · | 6/7 | 2011 US |
| Axitinib · Inlyta | Small-molecule kinase inhibitor (VEGFR) | 2012 | 2012 | 2012 | 2012 | 2015 | 2012 | · | 6/7 | 2012 US/EU/UK/JP/AU |
| Bosutinib · Bosulif | Small-molecule BCR-ABL1/SRC TKI | 2012 | 2013 | 2013 | 2014 | · | · | 5/7 | 2012 US | |
| Cabozantinib · Cabometyx | Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET) | 2012 | 2014 | 2014 | 2020 | 2023 | 2017 | · | 6/7 | 2012 US |
| Carfilzomib · Kyprolis | Proteasome inhibitor (irreversible) | 2012 | 2015 | 2015 | 2016 | 2021 | 2015 | · | 6/7 | 2012 US |
| Decitabine · Dacogen | Hypomethylating agent (DNA methyltransferase inhibitor) | · | 2012 | · | · | · | · | · | 1/7 | 2012 EU |
| Enzalutamide · Xtandi | Small-molecule AR antagonist | 2012 | 2013 | 2013 | 2014 | 2019 | 2014 | · | 6/7 | 2012 US |
| Granisetron · Kytril (historic) / Sancuso / Sustol | 5-HT3 receptor antagonist (antiemetic) | · | 2012 | · | · | · | · | · | 1/7 | 2012 EU |
| Mercaptopurine · Purinethol / Purixan | Thiopurine antimetabolite | · | 2012 | · | · | · | · | · | 1/7 | 2012 EU |
| Mogamulizumab · Poteligeo | Defucosylated anti-CCR4 monoclonal antibody | 2018 | 2018 | 2018 | 2012 | · | · | · | 4/7 | 2012 JP |
| Pertuzumab · Perjeta; Phesgo (with trastuzumab, subcutaneous) | Monoclonal antibody (anti-HER2, dimerisation domain) | 2012 | 2013 | 2013 | 2013 | 2018 | 2013 | · | 6/7 | 2012 US |
| Ponatinib · Iclusig | Small-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I) | 2012 | 2013 | 2013 | 2016 | · | 2015 | · | 5/7 | 2012 US |
| Regorafenib · Stivarga | Small-molecule multi-kinase inhibitor | 2012 | 2013 | 2013 | 2013 | 2017 | 2013 | · | 6/7 | 2012 US |
| Vismodegib · Erivedge | Small-molecule smoothened (hedgehog) inhibitor | 2012 | 2013 | 2013 | · | · | · | 4/7 | 2012 US | |
| Afatinib · Gilotrif / Giotrif | Small-molecule pan-ErbB TKI (second generation, irreversible) | 2013 | 2013 | 2013 | 2014 | 2017 | · | 6/7 | 2013 US/EU/UK | |
| Dabrafenib · Tafinlar | Small-molecule BRAF kinase inhibitor | · | 2013 | · | · | 2019 | · | · | 2/7 | 2013 EU |
| Dabrafenib + trametinib · Tafinlar + Mekinist | Small-molecule kinase inhibitors (BRAF + MEK) | 2014 | 2013 | 2013 | 2016 | 2019 | 2013 | · | 6/7 | 2013 EU/UK/AU |
| Ibrutinib · Imbruvica | Small-molecule covalent BTK inhibitor (first generation) | 2013 | 2014 | 2014 | 2016 | 2017 | 2015 | · | 6/7 | 2013 US |
| Lipegfilgrastim · Lonquex | Glycopegylated recombinant G-CSF | · | 2013 | · | · | · | · | · | 1/7 | 2013 EU |
| Obinutuzumab · Gazyva | Monoclonal antibody (anti-CD20, glycoengineered type II) | 2013 | 2014 | 2014 | 2018 | 2021 | 2014 | · | 6/7 | 2013 US |
| Pomalidomide · Pomalyst / Imnovid | Oral cereblon E3 ligase modulator (IMiD) | 2013 | 2013 | 2013 | 2015 | 2020 | · | 6/7 | 2013 US/EU/UK | |
| Radium-223 dichloride · Xofigo | Targeted alpha therapy (bone-seeking) | 2013 | 2013 | 2013 | 2016 | 2020 | 2014 | · | 6/7 | 2013 US/EU/UK |
| Technetium-99m tilmanocept · Lymphoseek | Radiopharmaceutical lymphatic mapping agent | 2013 | 2024 | 2014 | · | · | · | · | 2/7 | 2013 US |
| Trastuzumab emtansine · Kadcyla | ADC | 2013 | 2013 | 2013 | 2013 | 2020 | 2013 | · | 6/7 | 2013 US/EU/UK/JP/AU |
| Ziv-aflibercept · Zaltrap | Recombinant fusion protein (VEGF ligand trap) | · | 2013 | · | · | · | · | · | 1/7 | 2013 EU |
| Alectinib · Alecensa | Small-molecule kinase inhibitor (ALK) | 2015 | 2017 | 2017 | 2014 | 2018 | 2016 | · | 6/7 | 2014 JP |
| Belinostat · Beleodaq | Pan-HDAC inhibitor (hydroxamate) | 2014 | · | · | · | · | · | · | 1/7 | 2014 US |
| Blinatumomab · Blincyto | Bispecific T-cell engager (CD19×CD3) | 2014 | 2015 | 2015 | 2018 | 2020 | 2016 | · | 6/7 | 2014 US |
| Ceritinib · Zykadia | Small-molecule ALK TKI (second generation) | 2014 | 2015 | 2015 | 2016 | 2018 | · | 6/7 | 2014 US | |
| Idelalisib · Zydelig | Small-molecule PI3Kδ inhibitor | 2014 | 2014 | 2014 | · | · | · | 4/7 | 2014 US/EU/UK | |
| Nintedanib · Ofev (fibrosis); Vargatef (NSCLC, EU) | Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR) | · | 2014 | 2014 | · | · | · | · | 2/7 | 2014 EU/UK |
| Nivolumab · Opdivo / Opdivo Qvantig (SC) | Monoclonal antibody (anti-PD-1) | 2014 | 2015 | 2015 | 2014 | 2018 | 2016 | · | 6/7 | 2014 US/JP |
| Nonavalent HPV vaccine · Gardasil 9 | Prophylactic vaccine (virus-like particles) | 2014 | 2015 | 2015 | 2020 | 2018 | 2015 | · | 6/7 | 2014 US |
| Olaparib · Lynparza | Small-molecule PARP inhibitor | 2014 | 2014 | 2014 | 2018 | 2018 | 2016 | · | 6/7 | 2014 US/EU/UK |
| Pembrolizumab · Keytruda / Keytruda Qlex (SC) | Monoclonal antibody (anti-PD-1) | 2014 | 2015 | 2015 | 2016 | 2018 | 2015 | · | 6/7 | 2014 US |
| Ramucirumab · Cyramza | Monoclonal antibody (anti-VEGFR2) | 2014 | 2014 | 2014 | 2015 | 2022 | 2015 | · | 6/7 | 2014 US/EU/UK |
| Rivoceranib (apatinib) · Aitan | Small-molecule VEGFR2 TKI | · | · | · | 2014 | · | · | 1/7 | 2014 CN | |
| Trametinib · Mekinist | Small-molecule allosteric MEK1/2 inhibitor | · | 2014 | · | · | · | · | · | 1/7 | 2014 EU |
| Trifluridine/tipiracil · Lonsurf | Cytotoxic chemotherapy (oral nucleoside) | 2015 | 2016 | 2016 | 2014 | 2019 | 2018 | · | 6/7 | 2014 JP |
| Tucidinostat (chidamide) · Epidaza | Small-molecule oral subtype-selective HDAC inhibitor | · | · | 2021 | 2014 | · | · | 2/7 | 2014 CN | |
| Cobimetinib · Cotellic | Small-molecule kinase inhibitor (MEK1/2) | 2015 | 2015 | 2015 | 2018 | · | 2016 | · | 5/7 | 2015 US/EU/UK |
| Daratumumab · Darzalex / Darzalex Faspro (SC) | Monoclonal antibody (anti-CD38) | 2015 | 2016 | 2016 | 2017 | 2019 | 2016 | · | 6/7 | 2015 US |
| Dinutuximab (ch14.18) / dinutuximab beta · Unituxin / Qarziba (EU) | Monoclonal antibody (anti-GD2, chimeric) | 2015 | 2017 | 2017 | 2021 | · | 2020 | · | 5/7 | 2015 US |
| Elotuzumab · Empliciti | Anti-SLAMF7 monoclonal antibody | 2015 | 2016 | 2016 | 2016 | · | · | 5/7 | 2015 US | |
| Ixazomib · Ninlaro | Oral proteasome inhibitor (boronate) | 2015 | 2016 | 2016 | 2017 | 2018 | · | 6/7 | 2015 US | |
| Lenvatinib · Lenvima | Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT) | 2015 | 2015 | 2015 | 2015 | 2018 | 2015 | · | 6/7 | 2015 US/EU/UK/JP/AU |
| Osimertinib · Tagrisso | Small-molecule kinase inhibitor (EGFR) | 2015 | 2016 | 2016 | 2016 | 2017 | 2016 | · | 6/7 | 2015 US |
| Palbociclib · Ibrance | Small-molecule CDK4/6 inhibitor | 2015 | 2016 | 2016 | 2017 | 2018 | 2017 | · | 6/7 | 2015 US |
| Panobinostat · Farydak | Pan-HDAC inhibitor | 2022 | 2015 | · | · | · | · | · | 1/7 | 2015 EU |
| Sonidegib · Odomzo | Small-molecule smoothened inhibitor | 2015 | 2015 | 2015 | · | · | · | 4/7 | 2015 US/EU/UK | |
| Talimogene laherparepvec · Imlygic | Oncolytic virus (HSV-1) | 2015 | 2015 | 2016 | · | · | 2016 | · | 4/7 | 2015 US/EU |
| Atezolizumab · Tecentriq / Tecentriq Hybreza (SC) | Monoclonal antibody (anti-PD-L1) | 2016 | 2017 | 2017 | 2018 | 2020 | 2017 | · | 6/7 | 2016 US |
| Dexamethasone · Decadron (historic) / Hemady / Neofordex | Glucocorticoid | · | 2016 | · | · | · | · | · | 1/7 | 2016 EU |
| Fluciclovine F-18 · Axumin | PET radiotracer (synthetic amino acid) | 2016 | 2017 | 2017 | 2021 | · | · | · | 4/7 | 2016 US |
| Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet | PET radiotracer (somatostatin receptor ligand) | 2016 | · | · | · | · | 3/7 | 2016 US | ||
| NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen | Cytotoxic regimen | 2024 | 2016 | 2016 | · | · | 2018 | · | 4/7 | 2016 EU/UK |
| Rucaparib · Rubraca | Small-molecule PARP inhibitor | 2016 | 2018 | 2018 | · | · | 2020 | · | 4/7 | 2016 US |
| Venetoclax · Venclexta | Small-molecule BCL-2 inhibitor | 2016 | 2016 | 2016 | 2019 | 2020 | 2017 | · | 6/7 | 2016 US/EU/UK |
| Abemaciclib · Verzenio | Small-molecule CDK4/6 inhibitor | 2017 | 2018 | 2018 | 2018 | 2020 | 2019 | · | 6/7 | 2017 US |
| Acalabrutinib · Calquence | Small-molecule covalent BTK inhibitor (second generation) | 2017 | 2020 | 2020 | 2021 | 2023 | 2020 | · | 6/7 | 2017 US |
| Avelumab · Bavencio | Monoclonal antibody (anti-PD-L1) | 2017 | 2017 | 2017 | 2017 | 2020 | 2018 | · | 6/7 | 2017 US/EU/UK/JP |
| Axicabtagene ciloleucel · Yescarta | CAR-T (CD19) | 2017 | 2018 | 2018 | 2021 | 2021 | 2019 | · | 6/7 | 2017 US |
| Brigatinib · Alunbrig | Small-molecule ALK/EGFR TKI (second generation) | 2017 | 2018 | 2018 | 2021 | 2022 | · | 6/7 | 2017 US | |
| CPX-351 (liposomal daunorubicin-cytarabine) · Vyxeos | Liposomal cytotoxic formulation | 2017 | 2018 | 2018 | 2024 | · | 2021 | · | 5/7 | 2017 US |
| Durvalumab · Imfinzi | Monoclonal antibody (anti-PD-L1) | 2017 | 2018 | 2018 | 2018 | 2019 | 2018 | · | 6/7 | 2017 US |
| Enasidenib · Idhifa | Small-molecule IDH2 inhibitor | 2017 | 2021 | · | · | · | · | 1/7 | 2017 US | |
| FoundationOne CDx / Liquid CDx | Comprehensive genomic profiling test | 2017 | 2019 | · | 2018 | · | · | · | 3/7 | 2017 US |
| Inotuzumab ozogamicin · Besponsa | ADC | 2017 | 2017 | 2017 | 2018 | 2021 | 2018 | · | 6/7 | 2017 US/EU/UK |
| Lutetium-177 dotatate · Lutathera | Radioligand therapy (beta) | 2018 | 2017 | 2018 | 2021 | 2024 | 2018 | · | 6/7 | 2017 EU |
| Mechlorethamine (chlormethine) · Mustargen (historic) / Valchlor gel | Alkylating agent (nitrogen mustard); intravenous and topical gel | · | 2017 | · | · | · | · | · | 1/7 | 2017 EU |
| Midostaurin · Rydapt | Small-molecule multikinase inhibitor (FLT3) | 2017 | 2017 | 2017 | 2019 | 2021 | 2017 | · | 6/7 | 2017 US/EU/UK/AU |
| Neratinib · Nerlynx | Small-molecule irreversible pan-HER kinase inhibitor | 2017 | 2018 | 2018 | · | · | 2019 | · | 4/7 | 2017 US |
| Niraparib · Zejula | Small-molecule PARP inhibitor | 2017 | 2017 | 2017 | 2020 | 2019 | 2018 | · | 6/7 | 2017 US/EU/UK |
| Padeliporfin · Tookad | Intravenous photosensitiser for vascular-targeted photodynamic therapy | · | 2017 | · | · | · | · | · | 1/7 | 2017 EU |
| Ribociclib · Kisqali | Small-molecule CDK4/6 inhibitor | 2017 | 2017 | 2017 | 2019 | 2023 | 2017 | · | 6/7 | 2017 US/EU/UK/AU |
| Telotristat ethyl · Xermelo | Oral tryptophan hydroxylase inhibitor | · | 2017 | · | · | · | · | · | 1/7 | 2017 EU |
| Tisagenlecleucel · Kymriah | CAR-T (CD19) | 2017 | 2018 | 2018 | 2019 | 2018 | · | 5/7 | 2017 US | |
| Tivozanib · Fotivda | Small-molecule kinase inhibitor (VEGFR) | 2021 | 2017 | 2017 | · | · | · | · | 3/7 | 2017 EU/UK |
| Trastuzumab biosimilars · Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi | Biosimilar monoclonal antibody (anti-HER2) | 2017 | 2017 | 2018 | 2018 | 2020 | 2018 | · | 6/7 | 2017 US/EU |
| Anlotinib · Focus V | Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT) | 2026 | · | · | 2018 | · | · | 1/7 | 2018 CN | |
| Apalutamide · Erleada | Small-molecule AR antagonist | 2018 | 2019 | 2019 | 2019 | 2019 | 2018 | · | 6/7 | 2018 US/AU |
| Binimetinib · Mektovi | Small-molecule kinase inhibitor (MEK1/2) | 2018 | 2018 | 2018 | 2019 | · | 2019 | · | 5/7 | 2018 US/EU/UK |
| Burosumab · Crysvita | Monoclonal antibody (anti-FGF23) | · | 2018● | · | · | · | · | · | 1/7 | 2018 EU |
| Carmustine · BiCNU / Gliadel Wafer | Alkylating agent (nitrosourea); intravenous and implantable wafer | · | 2018 | · | · | · | · | · | 1/7 | 2018 EU |
| Cemiplimab · Libtayo | Monoclonal antibody (anti-PD-1) | 2018 | 2019 | 2019 | 2022 | · | 2020 | · | 5/7 | 2018 US |
| Dacomitinib · Vizimpro | Small-molecule pan-ErbB TKI (second generation, irreversible) | 2018 | 2019 | 2019 | 2019 | 2019 | · | 6/7 | 2018 US | |
| Daunorubicin · Cerubidine (historic) | Anthracycline (topoisomerase II inhibitor) | · | 2018 | · | · | · | · | · | 1/7 | 2018 EU |
| Duvelisib · Copiktra | Small-molecule PI3Kδ/γ inhibitor | 2018 | 2026 | · | · | · | · | · | 1/7 | 2018 US |
| Encorafenib · Braftovi | Small-molecule kinase inhibitor (BRAF) | 2018 | 2018 | 2018 | 2019 | 2023 | 2019 | · | 6/7 | 2018 US/EU/UK |
| Fruquintinib · Fruzaqla | Small-molecule kinase inhibitor (VEGFR1-3) | 2023 | 2024 | 2024 | 2024 | 2018 | 2025 | · | 6/7 | 2018 CN |
| Gilteritinib · Xospata | Small-molecule kinase inhibitor (FLT3, type I) | 2018 | 2019 | 2019 | 2018 | 2021 | 2019 | · | 6/7 | 2018 US/JP |
| Glasdegib · Daurismo | Small-molecule smoothened (hedgehog) inhibitor | 2018 | 2020 | 2020 | · | · | · | · | 3/7 | 2018 US |
| Ivosidenib · Tibsovo | Small-molecule IDH1 inhibitor | 2018 | 2023 | 2023 | 2025 | 2022 | 2023 | · | 6/7 | 2018 US |
| Larotrectinib · Vitrakvi | Small-molecule pan-TRK inhibitor (first generation) | 2018 | 2019 | 2019 | 2021 | 2022 | · | 6/7 | 2018 US | |
| Lorlatinib · Lorbrena | Small-molecule kinase inhibitor (ALK/ROS1) | 2018 | 2019 | 2019 | 2018 | 2022 | 2019 | · | 6/7 | 2018 US/JP |
| Mecapegfilgrastim | Long-acting granulocyte colony-stimulating factor (growth factor support) | · | · | · | · | 2018 | · | · | 1/7 | 2018 CN |
| Pyrotinib · Airuini | Small-molecule irreversible pan-HER kinase inhibitor | · | · | · | 2018 | · | · | 1/7 | 2018 CN | |
| Sintilimab · Tyvyt | Monoclonal antibody (anti-PD-1, IgG4) | 2022 | · | · | 2018 | · | · | 1/7 | 2018 CN | |
| Tagraxofusp · Elzonris | Recombinant cytotoxin (IL-3 fused to diphtheria toxin) | 2018 | 2021 | 2021 | 2025 | · | · | · | 4/7 | 2018 US |
| Talazoparib · Talzenna | Small-molecule PARP inhibitor | 2018 | 2019 | 2019 | 2024 | 2021 | 2019 | · | 6/7 | 2018 US |
| Toripalimab · Loqtorzi | Monoclonal antibody (anti-PD-1) | 2023 | 2024 | 2025 | · | 2018 | 2025 | · | 5/7 | 2018 CN |
| Alpelisib · Piqray | Small-molecule PI3Kα inhibitor | 2019 | 2020 | 2020 | 2022 | 2024 | 2020 | · | 6/7 | 2019 US |
| Camrelizumab · AiRuiKa | Monoclonal antibody (anti-PD-1) | · | · | 2019 | · | · | 1/7 | 2019 CN | ||
| Darolutamide · Nubeqa | Small-molecule AR antagonist | 2019 | 2020 | 2020 | 2020 | 2021 | 2020 | · | 6/7 | 2019 US |
| Enfortumab vedotin · Padcev | ADC | 2019 | 2022 | 2022 | 2021 | 2023 | · | 5/7 | 2019 US | |
| Entrectinib · Rozlytrek | Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant) | 2019 | 2020 | 2020 | 2019 | 2022 | · | 6/7 | 2019 US/JP | |
| Erdafitinib · Balversa | Small-molecule kinase inhibitor (pan-FGFR) | 2019 | 2024 | 2024 | 2024 | · | 2025 | · | 5/7 | 2019 US |
| Fedratinib · Inrebic | Small-molecule JAK2/FLT3 inhibitor | 2019 | 2021 | 2025 | · | · | 5/7 | 2019 US | ||
| Flumatinib | Oral second-generation BCR-ABL tyrosine kinase inhibitor | · | · | · | · | 2019 | · | · | 1/7 | 2019 CN |
| Luspatercept · Reblozyl | Erythroid maturation agent (activin receptor IIB ligand trap, Fc fusion) | 2019 | 2020 | 2020 | 2024 | · | · | 5/7 | 2019 US | |
| Pexidartinib · Turalio | Small-molecule CSF1R/KIT/FLT3 inhibitor | 2019 | 2020 | · | · | · | · | · | 1/7 | 2019 US |
| Polatuzumab vedotin · Polivy | ADC | 2019 | 2020 | 2020 | 2021 | 2023 | 2020 | · | 6/7 | 2019 US |
| Quizartinib · Vanflyta | Small-molecule kinase inhibitor (FLT3-ITD, type II) | 2023 | 2023 | 2024 | 2019 | 2025 | · | · | 5/7 | 2019 JP |
| Relugolix · Orgovyx | Oral GnRH antagonist | 2020 | 2022 | 2022 | 2019 | · | 2023 | · | 5/7 | 2019 JP |
| Ropeginterferon alfa-2b · Besremi | Long-acting mono-pegylated interferon alfa | 2021 | 2019 | 2019 | 2023 | · | · | · | 4/7 | 2019 EU/UK |
| Selinexor · Xpovio | Small-molecule XPO1 (nuclear export) inhibitor | 2019 | 2021 | 2021 | · | 2021 | 2022 | · | 5/7 | 2019 US |
| Tislelizumab · Tevimbra | Monoclonal antibody (anti-PD-1) | 2024 | 2023 | 2024 | 2025 | 2019 | 2024 | · | 6/7 | 2019 CN |
| Trastuzumab deruxtecan · Enhertu | ADC | 2019 | 2021 | 2021 | 2020 | 2023 | 2022 | · | 6/7 | 2019 US |
| Treosulfan · Grafapex | Alkylating conditioning agent (busulfan analogue) | 2025 | 2019 | 2019 | · | · | · | · | 3/7 | 2019 EU/UK |
| Zanubrutinib · Brukinsa | Small-molecule covalent BTK inhibitor (second generation) | 2019 | 2021 | 2021 | 2024 | 2020 | 2020 | · | 6/7 | 2019 US |
| Aumolertinib · Ameile | Small-molecule third-generation EGFR TKI | 2026 | · | · | 2020 | · | · | 2/7 | 2020 CN | |
| Avapritinib · Ayvakit | Small-molecule kinase inhibitor (PDGFRA D842V / KIT) | 2020 | 2020 | 2020 | · | 2021 | 2022 | · | 5/7 | 2020 US/EU/UK |
| Belantamab mafodotin · Blenrep | ADC | 2020 | 2025● | 2025 | 2025 | 2025 | · | 5/7 | 2020 US | |
| Brexucabtagene autoleucel · Tecartus | Autologous CD19 CAR-T (CD28 costimulatory domain) | 2020 | 2020 | 2020 | · | · | · | 4/7 | 2020 US/EU/UK | |
| Capmatinib & tepotinib · Tabrecta / Tepmetko | Small-molecule kinase inhibitors (MET) | 2020 | 2022 | 2022 | 2020 | 2023 | 2021 | · | 6/7 | 2020 US/JP |
| Cetuximab sarotalocan · Akalux | Photoimmunotherapy conjugate (anti-EGFR antibody-IR700 dye) | · | · | 2020 | · | · | · | 1/7 | 2020 JP | |
| Decitabine + cedazuridine (oral) · Inqovi | Oral hypomethylating agent | 2020 | 2023 | 2023 | · | · | 2022 | · | 4/7 | 2020 US |
| Ensartinib · Ensacove | Small-molecule ALK TKI (second generation) | 2024 | · | · | 2020 | · | · | 2/7 | 2020 CN | |
| Fluoroestradiol F-18 (FES PET) · Cerianna | PET radiotracer (oestrogen receptor ligand) | 2020 | · | · | · | · | · | · | 1/7 | 2020 US |
| Fluzoparib | Oral PARP inhibitor | · | · | · | · | 2020 | · | · | 1/7 | 2020 CN |
| Gallium-68 gozetotide (PSMA-11) · Illuccix / Gozellix / Locametz | PET imaging agent | 2020 | 2022 | 2022 | 2025 | · | 2021 | · | 5/7 | 2020 US |
| Inetetamab | Anti-HER2 monoclonal antibody, Fc-engineered | · | · | · | · | 2020 | · | · | 1/7 | 2020 CN |
| Isatuximab · Sarclisa / Sarclisa Escena (SC) | Monoclonal antibody (anti-CD38) | 2020 | 2020 | 2020 | 2020 | 2022 | 2020 | · | 6/7 | 2020 US/EU/UK/JP/AU |
| Lurbinectedin · Zepzelca | Cytotoxic (transcription inhibitor) | 2020 | 2026● | · | · | · | 2023 | · | 3/7 | 2020 US |
| Margetuximab · Margenza | Fc-engineered monoclonal antibody (anti-HER2) | 2020 | 2022 | · | · | 2024 | · | · | 2/7 | 2020 US |
| Naxitamab · Danyelza | Monoclonal antibody (anti-GD2, humanised) | 2020 | · | · | 2024 | · | · | 2/7 | 2020 US | |
| Orelabrutinib · Yinuokai | Small-molecule covalent BTK inhibitor (second generation) | · | · | · | 2020 | · | · | 1/7 | 2020 CN | |
| Pemigatinib · Pemazyre | Small-molecule kinase inhibitor (FGFR1-3) | 2020 | 2021 | 2021 | 2021 | 2022 | 2022 | · | 6/7 | 2020 US |
| Pralsetinib · Gavreto | Small-molecule kinase inhibitor (RET) | 2020 | 2024 | 2021 | · | 2021 | 2022 | · | 4/7 | 2020 US |
| Ripretinib · Qinlock | Small-molecule kinase inhibitor (KIT/PDGFRA switch-control) | 2020 | 2021 | 2021 | · | 2021 | 2020 | · | 5/7 | 2020 US/AU |
| Sacituzumab govitecan · Trodelvy | ADC | 2020 | 2021 | 2021 | 2024 | 2022 | 2022 | · | 6/7 | 2020 US |
| Selpercatinib · Retevmo | Small-molecule kinase inhibitor (RET) | 2020 | 2021 | 2021 | 2021 | 2022 | 2021 | · | 6/7 | 2020 US |
| Surufatinib | Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor | · | · | · | 2020 | · | · | 1/7 | 2020 CN | |
| Tafasitamab · Monjuvi | Monoclonal antibody (anti-CD19, Fc-enhanced) | 2020 | 2021 | 2021 | 2025 | · | 2022 | · | 5/7 | 2020 US |
| Tucatinib · Tukysa | Small-molecule kinase inhibitor (HER2) | 2020 | 2021 | 2021 | 2026 | 2023 | 2021 | · | 6/7 | 2020 US |
| Amivantamab · Rybrevant | Bispecific antibody (EGFR×MET) | 2021 | 2021 | 2022 | 2024 | 2024 | 2023 | · | 6/7 | 2021 US/EU |
| Asciminib · Scemblix | Small-molecule allosteric ABL1 inhibitor (STAMP) | 2021 | 2022 | 2022 | 2022 | 2023 | 2022 | · | 6/7 | 2021 US |
| Belumosudil · Rezurock | Oral ROCK2 inhibitor | 2021 | · | · | · | · | 3/7 | 2021 US | ||
| Belzutifan · Welireg | Small-molecule HIF-2α inhibitor | 2021 | 2025● | 2025 | 2025 | · | 2025 | · | 5/7 | 2021 US |
| Dalpiciclib · Airuikang | Small-molecule CDK4/6 inhibitor | · | · | · | 2021 | · | · | 1/7 | 2021 CN | |
| Disitamab vedotin | ADC | · | · | · | 2021 | · | · | 1/7 | 2021 CN | |
| Donafenib · Zepsun | Small-molecule multi-kinase inhibitor (deuterated sorafenib) | · | · | · | 2021 | · | · | 1/7 | 2021 CN | |
| Dostarlimab · Jemperli | Monoclonal antibody (anti-PD-1) | 2021 | 2021 | 2021 | · | · | 2023 | · | 4/7 | 2021 US/EU/UK |
| Envafolimab · Enweida | Single-domain antibody (anti-PD-L1, subcutaneous) | · | · | · | 2021 | · | · | 1/7 | 2021 CN | |
| Furmonertinib · Ivesa | Small-molecule third-generation EGFR TKI | · | · | · | 2021 | · | · | 1/7 | 2021 CN | |
| Idecabtagene vicleucel · Abecma | CAR-T (BCMA) | 2021 | 2021 | 2021 | 2022 | · | 2022 | · | 5/7 | 2021 US/EU/UK |
| Lisocabtagene maraleucel · Breyanzi | CAR-T (CD19, defined CD4:CD8) | 2021 | 2022 | 2022 | 2021 | · | 2022 | · | 5/7 | 2021 US/JP |
| Loncastuximab tesirine · Zynlonta | ADC | 2021 | 2022 | 2023 | · | 2025 | · | · | 4/7 | 2021 US |
| Olverembatinib | Oral third-generation BCR-ABL tyrosine kinase inhibitor | · | · | · | · | 2021 | · | · | 1/7 | 2021 CN |
| Pafolacianine · Cytalux | Folate receptor-targeted near-infrared fluorescent imaging agent | 2021 | · | · | · | · | · | · | 1/7 | 2021 US |
| Pamiparib | Oral PARP inhibitor | · | · | · | · | 2021 | · | · | 1/7 | 2021 CN |
| Penpulimab · Penpulimab-kcqx | Anti-PD-1 monoclonal antibody (IgG1, Fc-engineered null) | 2025 | · | · | · | 2021 | · | · | 2/7 | 2021 CN |
| Piflufolastat F-18 / Pylarify TruVu · Pylarify | PET imaging agent | 2021 | 2023● | 2023 | · | · | · | · | 3/7 | 2021 US |
| Relmacabtagene autoleucel · Carteyva | Cell therapy (autologous CD19 CAR-T, 4-1BB) | · | · | · | 2021 | · | · | 1/7 | 2021 CN | |
| Savolitinib · Orpathys | Small-molecule selective MET TKI | · | · | 2021 | · | · | 1/7 | 2021 CN | ||
| Selumetinib · Koselugo | Small-molecule allosteric MEK1/2 inhibitor | · | 2021 | · | · | · | · | · | 1/7 | 2021 EU |
| Sotorasib · Lumakras | Small-molecule inhibitor (KRAS G12C) | 2021 | 2022 | 2021 | 2022 | 2022 | · | 5/7 | 2021 US/UK | |
| Sugemalimab · Cejemly | Monoclonal antibody (anti-PD-L1, fully human IgG4) | 2024 | · | 2021 | · | · | 2/7 | 2021 CN | ||
| Tisotumab vedotin · Tivdak | ADC | 2021 | 2025● | 2025 | 2025 | · | · | · | 4/7 | 2021 US |
| Utidelone | Epothilone analogue, microtubule-stabilising cytotoxic chemotherapy | · | · | · | · | 2021 | · | · | 1/7 | 2021 CN |
| Zimberelimab | Anti-PD-1 monoclonal antibody, intravenous | · | · | · | · | 2021 | · | · | 1/7 | 2021 CN |
| Adagrasib · Krazati | Small-molecule inhibitor (KRAS G12C) | 2022 | 2024● | 2024 | · | 2024 | · | 4/7 | 2022 US | |
| Cadonilimab · Kaitanni | Bispecific antibody (PD-1×CTLA-4) | · | · | · | 2022 | · | · | 1/7 | 2022 CN | |
| Capmatinib · Tabrecta | Small-molecule MET tyrosine kinase inhibitor | · | 2022 | · | · | · | · | · | 1/7 | 2022 EU |
| CERVAVAC (quadrivalent HPV vaccine, India) · CERVAVAC | Prophylactic vaccine (virus-like particles) | · | · | · | · | · | · | 2022 | 1/7 | 2022 IN |
| Ciltacabtagene autoleucel · Carvykti | CAR-T (BCMA) | 2022 | 2022 | 2022 | 2022 | 2024 | 2023 | · | 6/7 | 2022 US/EU/UK/JP |
| Futibatinib · Lytgobi | Small-molecule irreversible kinase inhibitor (FGFR1-4) | 2022 | 2023 | 2023 | 2023 | · | · | · | 4/7 | 2022 US |
| Linperlisib | Oral PI3K-delta inhibitor | · | · | · | · | 2022 | · | · | 1/7 | 2022 CN |
| Lutetium-177 vipivotide tetraxetan · Pluvicto | Radioligand therapy (beta) | 2022 | 2022 | 2023 | 2025 | 2023 | · | 5/7 | 2022 US/EU | |
| Melphalan flufenamide · Pepaxto | Peptide-drug conjugate | 2021 | 2022 | · | · | · | · | · | 1/7 | 2022 EU |
| Mirvetuximab soravtansine · Elahere | ADC | 2022 | 2024● | 2025 | · | 3/7 | 2022 US | |||
| Mosunetuzumab · Lunsumio | Bispecific T-cell engager (CD20×CD3) | 2022 | 2022 | 2022 | 2024 | · | 2023 | · | 5/7 | 2022 US/EU/UK |
| Nadofaragene firadenovec · Adstiladrin | Non-replicating adenoviral gene therapy (intravesical) | 2022 | 2026● | · | · | · | · | 2/7 | 2022 US | |
| Olutasidenib · Rezlidhia | Small-molecule IDH1 inhibitor | 2022 | · | · | · | · | · | 1/7 | 2022 US | |
| Pacritinib · Vonjo | Small-molecule JAK2/IRAK1/ACVR1 inhibitor | 2022 | · | · | · | · | · | · | 1/7 | 2022 US |
| Pucotenlimab | Anti-PD-1 monoclonal antibody, intravenous | · | · | · | · | 2022 | · | · | 1/7 | 2022 CN |
| Relatlimab + nivolumab · Opdualag | Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1) | 2022 | 2022 | 2023 | · | · | 2023 | · | 4/7 | 2022 US/EU |
| Rezvilutamide | Oral androgen receptor antagonist | · | · | · | · | 2022 | · | · | 1/7 | 2022 CN |
| Serplulimab · Hansizhuang / Hetronifly | Monoclonal antibody (anti-PD-1) | 2025 | 2025 | · | 2022 | · | · | 3/7 | 2022 CN | |
| Sodium thiosulfate (otoprotectant) · Pedmark | Small-molecule chemoprotectant | 2022 | 2023 | · | · | · | · | 3/7 | 2022 US | |
| Tebentafusp · Kimmtrak | ImmTAC (TCR×CD3 bispecific) | 2022 | 2022 | 2022 | · | 2023 | · | 4/7 | 2022 US/EU/UK | |
| Teclistamab · Tecvayli | Bispecific T-cell engager (BCMA×CD3) | 2022 | 2022 | 2022 | 2024 | 2025 | 2024 | · | 6/7 | 2022 US/EU/UK |
| Tepotinib · Tepmetko | Small-molecule MET tyrosine kinase inhibitor | · | 2022 | · | · | · | · | · | 1/7 | 2022 EU |
| Tremelimumab · Imjudo | Monoclonal antibody (anti-CTLA-4) | 2022 | 2023 | 2023 | 2022 | · | 2023 | · | 5/7 | 2022 US/JP |
| Adebrelimab · Arelili | Monoclonal antibody (anti-PD-L1, humanised IgG4) | · | · | · | 2023 | · | · | 1/7 | 2023 CN | |
| Befotertinib | Oral kinase inhibitor | · | · | · | · | 2023 | · | · | 1/7 | 2023 CN |
| Camrelizumab + rivoceranib | PD-1 antibody + oral VEGFR2 inhibitor | · | · | · | 2023 | · | · | 1/7 | 2023 CN | |
| Capivasertib · Truqap | Small-molecule AKT inhibitor | 2023 | 2024● | 2024 | 2024 | 2025 | 2024 | · | 6/7 | 2023 US |
| Crisantaspase (recombinant Erwinia asparaginase) · Enrylaze | Enzyme therapy (recombinant asparaginase) | · | 2023● | · | · | · | · | · | 1/7 | 2023 EU |
| Eflornithine (DFMO) · Iwilfin | Small-molecule ornithine decarboxylase inhibitor | 2023 | · | · | · | · | · | 1/7 | 2023 US | |
| Elacestrant · Orserdu | Oral SERD | 2023 | 2023 | 2024 | · | 2024 | · | 4/7 | 2023 US/EU | |
| Elranatamab · Elrexfio | Bispecific T-cell engager (BCMA×CD3) | 2023 | 2023 | 2024 | 2024 | · | 2024 | · | 5/7 | 2023 US/EU |
| Epcoritamab · Epkinly | Bispecific T-cell engager (CD20×CD3) | 2023 | 2023 | 2023 | 2023 | · | 2024 | · | 5/7 | 2023 US/EU/UK/JP |
| Equecabtagene autoleucel · Fucaso | Cell therapy (autologous BCMA CAR-T, fully human binder) | · | · | · | 2023 | · | · | 1/7 | 2023 CN | |
| Flotufolastat F-18 · Posluma | PET imaging agent | 2023 | · | · | · | · | · | 1/7 | 2023 US | |
| Glofitamab · Columvi | Bispecific T-cell engager (CD20×CD3, 2:1) | 2023 | 2023 | 2023 | 2024 | 2024 | 2024 | · | 6/7 | 2023 US/EU/UK |
| Glumetinib | Oral selective MET tyrosine kinase inhibitor | · | · | · | · | 2023 | · | · | 1/7 | 2023 CN |
| Inaticabtagene autoleucel · Yuanruida | Cell therapy (autologous CD19 CAR-T) | · | · | · | · | 2023 | · | · | 1/7 | 2023 CN |
| Iruplinalkib | Oral ALK and ROS1 tyrosine kinase inhibitor | · | · | · | · | 2023 | · | · | 1/7 | 2023 CN |
| Momelotinib · Ojjaara / Omjjara | Small-molecule JAK1/JAK2/ACVR1 inhibitor | 2023 | 2024 | 2024 | 2024 | · | · | · | 4/7 | 2023 US |
| Nirogacestat · Ogsiveo | Small-molecule gamma-secretase inhibitor | 2023 | 2025 | 2026 | · | · | · | · | 3/7 | 2023 US |
| Pirtobrutinib · Jaypirca | Small-molecule non-covalent (reversible) BTK inhibitor | 2023 | 2023 | 2024 | 2024 | · | · | · | 4/7 | 2023 US/EU |
| Repotrectinib · Augtyro | Small-molecule kinase inhibitor (ROS1 / NTRK) | 2023 | 2025● | 2025 | 2024 | 2025 | · | · | 5/7 | 2023 US |
| Retifanlimab · Zynyz | Anti-PD-1 monoclonal antibody (IgG4) | 2023 | 2024 | 2026 | 2025 | · | · | · | 4/7 | 2023 US |
| Sunvozertinib · Zegfrovy | Small-molecule EGFR exon 20 insertion TKI (irreversible) | 2025 | · | · | · | 2023 | · | · | 2/7 | 2023 CN |
| Talicabtagene autoleucel · NexCAR19 | CAR-T (CD19, humanised) | · | · | · | · | · | · | 2023 | 1/7 | 2023 IN |
| Talquetamab · Talvey | Bispecific T-cell engager (GPRC5D×CD3) | 2023 | 2023 | 2024 | 2025 | · | 2024 | · | 5/7 | 2023 US/EU |
| Vebreltinib | Oral selective MET tyrosine kinase inhibitor | · | · | · | · | 2023 | · | · | 1/7 | 2023 CN |
| Vorolanib | Oral multi-target VEGFR and PDGFR tyrosine kinase inhibitor | · | · | · | · | 2023 | · | · | 1/7 | 2023 CN |
| Afamitresgene autoleucel · Tecelra | TCR-T (MAGE-A4) | 2024 | · | · | · | · | · | 1/7 | 2024 US | |
| Benmelstobart | Anti-PD-L1 monoclonal antibody | · | · | · | · | 2024 | · | · | 1/7 | 2024 CN |
| Cosibelimab · Unloxcyt | Anti-PD-L1 monoclonal antibody (IgG1, ADCC-competent) | 2024 | · | · | · | · | · | · | 1/7 | 2024 US |
| Datopotamab deruxtecan · Datroway | ADC | 2025 | 2025● | 2025 | 2024 | · | 4/7 | 2024 JP | ||
| Efbemalenograstim alfa · Ryzneuta | Long-acting recombinant G-CSF dimer (Fc fusion) | · | 2024 | · | · | · | · | · | 1/7 | 2024 EU |
| Fulzerasib · Dupert | Small-molecule covalent KRAS G12C inhibitor | · | · | · | 2024 | · | · | 1/7 | 2024 CN | |
| Garsorasib | Small-molecule covalent KRAS G12C inhibitor | · | · | · | 2024 | · | · | 1/7 | 2024 CN | |
| Glecirasib | Oral covalent KRAS G12C inhibitor | · | · | · | · | 2024 | · | · | 1/7 | 2024 CN |
| Golidocitinib | Oral selective JAK1 inhibitor | · | · | · | · | 2024 | · | · | 1/7 | 2024 CN |
| Imetelstat · Rytelo | Telomerase inhibitor (oligonucleotide) | 2024 | 2025 | · | · | · | · | · | 2/7 | 2024 US |
| Inavolisib · Itovebi | Small-molecule PI3Kα inhibitor and degrader | 2024 | 2025● | 2025 | 2025 | 2025 | · | 5/7 | 2024 US | |
| Iparomlimab and tuvonralimab | Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4 | · | · | · | · | 2024 | · | · | 1/7 | 2024 CN |
| Ivonescimab | Bispecific antibody (PD-1×VEGF) | · | · | 2024 | · | · | 1/7 | 2024 CN | ||
| Lazertinib · Lazcluze | Small-molecule kinase inhibitor (EGFR) | 2024 | 2025● | 2025 | 2025 | 2025 | · | · | 5/7 | 2024 US |
| Lifileucel · Amtagvi | TIL cell therapy | 2024 | 2025 | · | · | 1/7 | 2024 US | |||
| Limertinib | Oral third-generation EGFR tyrosine kinase inhibitor | · | · | · | · | 2024 | · | · | 1/7 | 2024 CN |
| Nogapendekin alfa inbakicept · Anktiva | IL-15 superagonist (intravesical, with BCG) | 2024 | 2026● | 2025 | · | · | · | · | 3/7 | 2024 US |
| Obecabtagene autoleucel · Aucatzyl | CAR-T (CD19, fast off-rate) | 2024 | 2025● | 2025 | · | · | · | · | 3/7 | 2024 US |
| Odronextamab · Lynozyfic (EU: Ordspono) | Bispecific T-cell engager (CD20×CD3) | 2025 | 2024 | 2025 | · | · | · | · | 3/7 | 2024 EU |
| Pegulicianine · Lumisight | Protease-activated fluorescent imaging agent | 2024 | · | · | · | · | · | · | 1/7 | 2024 US |
| Revumenib · Revuforj | Small-molecule menin inhibitor | 2024 | · | · | · | · | · | 1/7 | 2024 US | |
| Sacituzumab tirumotecan | ADC | · | · | 2024 | · | · | 1/7 | 2024 CN | ||
| Shield | Blood-based colorectal cancer screening test | 2024 | · | · | · | · | · | 1/7 | 2024 US | |
| Tarlatamab · Imdelltra | Bispecific T-cell engager (DLL3×CD3) | 2024 | 2026● | 2024 | 2024 | · | · | 4/7 | 2024 US/UK/JP | |
| Tovorafenib · Ojemda | Small-molecule type II RAF inhibitor | 2024 | 2026 | 2026 | · | · | · | · | 3/7 | 2024 US |
| Tunlametinib | Oral MEK1/2 inhibitor | · | · | · | · | 2024 | · | · | 1/7 | 2024 CN |
| Varnimcabtagene autoleucel · Qartemi | CAR-T (CD19, academic origin) | · | · | · | · | · | · | 2024 | 1/7 | 2024 IN |
| Vorasidenib · Voranigo | Small-molecule IDH1/2 inhibitor | 2024 | 2025● | 2025 | · | 2025 | · | 4/7 | 2024 US | |
| Zanidatamab · Ziihera | Biparatopic bispecific antibody (HER2) | 2024 | 2025● | 2026 | · | 2025 | · | · | 4/7 | 2024 US |
| Zenocutuzumab · Bizengri | Bispecific antibody (HER2×HER3) | 2024 | · | · | · | · | · | 1/7 | 2024 US | |
| Zevorcabtagene autoleucel · Saikaize | Cell therapy (autologous BCMA CAR-T, fully human binder) | · | · | · | 2024 | · | · | 1/7 | 2024 CN | |
| Zolbetuximab · Vyloy | Monoclonal antibody (anti-Claudin 18.2) | 2024 | 2024● | 2024 | 2024 | 2025 | 2025 | · | 6/7 | 2024 US/EU/UK/JP |
| ArteraAI Prostate | AI digital pathology prognostic/predictive test | 2025 | · | · | · | · | · | · | 1/7 | 2025 US |
| Avutometinib + defactinib · Avmapki Fakzynja Co-Pack | Small-molecule RAF/MEK clamp + FAK inhibitor | 2025 | · | · | · | · | · | 1/7 | 2025 US | |
| Catumaxomab · Korjuny | Trifunctional bispecific antibody (EpCAM x CD3, rat-mouse hybrid) | · | 2025 | · | · | · | · | · | 1/7 | 2025 EU |
| Dordaviprone · Modeyso | Small-molecule imipridone (ClpP agonist / DRD2 antagonist) | 2025 | · | · | · | · | · | 1/7 | 2025 US | |
| Dorocubicel (UM171-expanded cord blood) · Zemcelpro | Allogeneic expanded cord blood cell therapy (ATMP) | · | 2025 | · | · | · | · | · | 1/7 | 2025 EU |
| Gemcitabine intravesical system (TAR-200) · Inlexzo | Intravesical drug-eluting device | 2025 | · | · | · | · | · | 1/7 | 2025 US | |
| Imlunestrant · Inluriyo | Oral SERD | 2025 | 2026● | 2026 | 2025 | · | · | · | 4/7 | 2025 US/JP |
| Linvoseltamab · Lynozyfic | Bispecific T-cell engager (BCMA×CD3) | 2025 | 2025● | 2025 | · | · | · | · | 3/7 | 2025 US/EU/UK |
| Mirdametinib · Gomekli / Ezmekly | Small-molecule allosteric MEK1/2 inhibitor | · | 2025 | · | · | · | · | · | 1/7 | 2025 EU |
| Satricabtagene autoleucel | CAR-T (Claudin 18.2) | · | · | · | 2025 | · | · | 1/7 | 2025 CN | |
| Sevabertinib · Hyrnuo | Small-molecule kinase inhibitor (HER2) | 2025 | 2026 | · | · | · | · | 2/7 | 2025 US | |
| Sonrotoclax · Beqalzi | Small-molecule BCL-2 inhibitor (second generation) | 2026 | · | · | · | 2025 | · | · | 2/7 | 2025 CN |
| Taletrectinib · Ibtrozi | Small-molecule ROS1 TKI (next generation, CNS-penetrant) | 2025 | · | · | 2025 | 2025 | · | · | 3/7 | 2025 US/JP/CN |
| Telisotuzumab vedotin · Emrelis | ADC | 2025 | · | · | · | · | · | 1/7 | 2025 US | |
| Trastuzumab rezetecan | ADC | · | · | · | · | 2025 | · | · | 1/7 | 2025 CN |
| Vimseltinib · Romvimza | Small-molecule kinase inhibitor (CSF1R) | 2025 | 2025● | 2026 | · | · | · | · | 3/7 | 2025 US/EU |
| Ziftomenib · Komzifti | Small-molecule menin inhibitor | 2025 | · | · | · | · | · | 1/7 | 2025 US | |
| Zongertinib · Hernexeos | Small-molecule kinase inhibitor (HER2) | 2025 | · | 2025 | 2025 | · | · | 3/7 | 2025 US/JP/CN | |
| ArteraAI Breast | AI digital pathology risk test | 2026 | · | · | · | · | · | · | 1/7 | 2026 US |
| Camizestrant · Etcamah | Oral SERD | 2026 | 2026● | · | · | · | · | · | 2/7 | 2026 US/EU |
| Daraxonrasib · Rasonque | Small-molecule pan-RAS(ON) inhibitor | 2026 | · | · | · | · | · | · | 1/7 | 2026 US |
| Gedatolisib · Revtorpyk | Small-molecule pan-PI3K/mTOR inhibitor | 2026 | · | · | · | · | · | 1/7 | 2026 US | |
| Iberdomide · Zenbexus | CELMoD (cereblon E3 ligase modulator) | 2026 | · | · | · | · | · | · | 1/7 | 2026 US |
| Lirafugratinib · Lyrfigtu | Small-molecule FGFR2 inhibitor | 2026 | · | · | · | · | 1/7 | 2026 US | ||
| Pivekimab sunirine · Decnupaz | ADC (anti-CD123 antibody, IGN payload) | 2026 | · | · | · | · | · | · | 1/7 | 2026 US |
| Relacorilant · Lifyorli | Small-molecule glucocorticoid receptor antagonist | 2026 | · | · | · | · | · | 1/7 | 2026 US | |
| Rusfertide · Mimrylo | Hepcidin mimetic peptide | 2026 | · | · | · | · | · | · | 1/7 | 2026 US |
| Vepdegestrant · Veppanu | PROTAC oestrogen receptor degrader | 2026 | · | · | · | · | · | 1/7 | 2026 US | |
| Vusolimogene oderparepvec · Tudriqev | Oncolytic virus (HSV-1) | 2026 | · | · | · | · | · | 1/7 | 2026 US | |
| Zidesamtinib · Jideytro | Small-molecule kinase inhibitor (ROS1) | 2026 | · | · | · | · | · | 1/7 | 2026 US | |
| 177Lu-edotreotide | Radioligand therapy (beta) | · | · | · | · | · | 0/7 | - | ||
| 177Lu-PSMA-I&T | Radioligand therapy (beta) | · | · | · | · | · | 0/7 | - | ||
| Actinium-225 DOTATATE | Targeted alpha therapy | · | · | · | · | · | · | 0/7 | - | |
| Actinium-225 PSMA agents | Targeted alpha therapy | · | · | · | · | · | · | 0/7 | - | |
| Alemtuzumab · Campath | Monoclonal antibody (anti-CD52) | · | 2012 | · | · | · | · | · | 0/7 | - |
| Anitocabtagene autoleucel | CAR-T (BCMA, D-domain binder) | · | · | · | · | · | · | 0/7 | - | |
| ARX788 | ADC | · | · | · | · | · | · | 0/7 | - | |
| Atirmociclib | Small-molecule CDK4-selective inhibitor | · | · | · | · | · | · | 0/7 | - | |
| Bemarituzumab | Monoclonal antibody (anti-FGFR2b) | · | · | · | · | · | 0/7 | - | ||
| BGB-16673 | Small-molecule BTK degrader (CDAC) | · | · | · | · | · | · | 0/7 | - | |
| Brenetafusp | ImmTAC (PRAME TCR × CD3 bispecific) | · | · | · | · | · | · | 0/7 | - | |
| Busulfan · Myleran / Busulfex | Alkylating agent (alkyl sulfonate) | · | 2023 | · | · | · | · | · | 0/7 | - |
| CAPOX (capecitabine, oxaliplatin) | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| Cediranib | Oral VEGFR 1-3 tyrosine kinase inhibitor | · | · | · | · | · | · | 0/7 | - | |
| Celecoxib · Celebrex | Oral COX-2 inhibitor | · | 2008 | · | · | · | · | · | 0/7 | - |
| Cinacalcet · Sensipar / Mimpara | Oral small-molecule calcimimetic | · | 2025 | · | · | · | · | · | 0/7 | - |
| Copanlisib · Aliqopa | Intravenous pan-class I PI3K inhibitor (α/δ predominant) | 2023 | · | · | · | · | · | 0/7 | - | |
| Cretostimogene grenadenorepvec | Oncolytic adenovirus (intravesical) | · | · | · | · | · | · | 0/7 | - | |
| Cytarabine · Cytosar-U (historic) | Pyrimidine nucleoside analogue (antimetabolite) | · | 2018 | · | · | · | · | · | 0/7 | - |
| DCVax-L | Autologous dendritic cell vaccine (tumour lysate) | · | · | · | · | · | 0/7 | - | ||
| Divarasib | Small-molecule inhibitor (KRAS G12C) | · | · | · | · | · | · | 0/7 | - | |
| Eryaspase | L-asparaginase encapsulated in donor red blood cells | · | · | · | · | · | · | 0/7 | - | |
| Fianlimab | Monoclonal antibody (anti-LAG-3) | · | · | · | · | · | · | 0/7 | - | |
| Ficerafusp alfa | Bifunctional antibody (EGFR × TGF-β trap) | · | · | · | · | · | · | 0/7 | - | |
| FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| FOLFIRI (5-FU, leucovorin, irinotecan) | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| FOLFIRINOX / mFOLFIRINOX | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| FOLFOX (5-FU, leucovorin, oxaliplatin) | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| Galleri | Multi-cancer early detection blood test | · | · | · | · | 0/7 | - | |||
| Gemcitabine + cisplatin | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| Gemcitabine + nab-paclitaxel · Gemzar + Abraxane | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| Giredestrant | Oral SERD | · | · | · | · | · | · | 0/7 | - | |
| Golcadomide | Molecular glue degrader (CELMoD, IKZF1/3) | · | · | · | · | · | · | 0/7 | - | |
| Ibritumomab tiuxetan · Zevalin | Radioimmunotherapy (yttrium-90 labelled anti-CD20 antibody) | · | 2024 | · | · | · | · | · | 0/7 | - |
| Ifinatamab deruxtecan | ADC | · | · | · | · | · | · | 0/7 | - | |
| Infigratinib · Truseltiq | Oral FGFR1 to 3 kinase inhibitor | · | · | · | · | · | · | 0/7 | - | |
| Intismeran autogene | Personalised mRNA neoantigen vaccine | · | · | · | · | · | · | 0/7 | - | |
| Ixabepilone · Ixempra | Epothilone B analogue (microtubule stabiliser) | · | · | · | · | · | · | 0/7 | - | |
| Izalontamab brengitecan | Bispecific ADC | · | · | · | · | · | 0/7 | - | ||
| Luveltamab tazevibulin | ADC | · | · | · | · | · | · | 0/7 | - | |
| Mevrometostat | Small-molecule EZH2 inhibitor | · | · | · | · | · | · | 0/7 | - | |
| Mezigdomide | CELMoD (cereblon E3 ligase modulator) | · | · | · | · | · | · | 0/7 | - | |
| Mobocertinib · Exkivity | Small-molecule EGFR exon 20 insertion TKI (irreversible) | 2023 | · | · | · | · | · | 0/7 | - | |
| Moxetumomab pasudotox · Lumoxiti | Anti-CD22 immunotoxin (Pseudomonas exotoxin A fragment) | 2023 | 2021 | · | · | · | · | · | 0/7 | - |
| Necitumumab · Portrazza | Monoclonal antibody (anti-EGFR, IgG1) | · | 2021 | · | · | · | · | · | 0/7 | - |
| Neladalkib | Small-molecule kinase inhibitor (ALK) | · | · | · | · | · | · | 0/7 | - | |
| Nemtabrutinib | Small-molecule non-covalent BTK inhibitor | · | · | · | · | · | · | 0/7 | - | |
| Nimotuzumab · BIOMAb EGFR / TheraCIM / CIMAher | Humanised anti-EGFR monoclonal antibody, intravenous | · | · | · | · | · | · | 0/7 | - | |
| Ofatumumab · Arzerra | Monoclonal antibody (anti-CD20, fully human IgG1) | · | 2019 | · | · | · | · | · | 0/7 | - |
| Olaratumab · Lartruvo | Anti-PDGFR alpha monoclonal antibody, intravenous | 2019 | 2019 | · | · | · | · | · | 0/7 | - |
| Olomorasib | Small-molecule inhibitor (KRAS G12C) | · | · | · | · | · | · | 0/7 | - | |
| Omacetaxine mepesuccinate · Synribo | Protein synthesis inhibitor (cephalotaxine ester) | · | · | · | · | · | · | 0/7 | - | |
| Parsaclisib | Oral PI3K inhibitor | · | · | · | · | · | · | 0/7 | - | |
| Pasritamig | Bispecific T-cell engager (KLK2×CD3) | · | · | · | · | · | · | 0/7 | - | |
| Patritumab deruxtecan | ADC | 2025 | · | · | · | · | · | · | 0/7 | - |
| Peginterferon alfa-2b · Sylatron / PegIntron | Pegylated type I interferon, weekly subcutaneous injection | · | · | · | · | · | · | 0/7 | - | |
| Petosemtamab | Bispecific antibody (EGFR × LGR5) | · | · | · | · | · | · | 0/7 | - | |
| Pixantrone · Pixuvri | Aza-anthracenedione cytotoxic, intravenous | · | 2024 | · | · | · | · | · | 0/7 | - |
| Platinum + etoposide (EP / CE) | Cytotoxic regimen | · | · | · | · | 3/7 | - | |||
| Plitidepsin · Aplidin | Marine-derived cyclic depsipeptide (small molecule), intravenous | · | · | · | · | · | · | 0/7 | - | |
| Porfimer sodium · Photofrin | Photosensitiser for photodynamic therapy, intravenous then laser light | · | 2012 | · | · | · | · | · | 0/7 | - |
| Raludotatug deruxtecan | ADC | · | · | · | · | · | · | 0/7 | - | |
| Resminostat · Kinselby | Small-molecule HDAC inhibitor | · | 2025 | · | · | · | · | · | 0/7 | - |
| Rinatabart sesutecan | ADC | · | · | · | · | · | · | 0/7 | - | |
| Rolapitant · Varubi | Neurokinin-1 receptor antagonist (antiemetic) | · | 2020 | · | · | · | · | · | 0/7 | - |
| Sasanlimab | monoclonal antibody | · | · | · | · | · | · | 0/7 | - | |
| Senaparib (IMP4297) · Sepalna | small molecule (oral PARP inhibitor) | · | · | · | · | · | · | 0/7 | - | |
| Sonesitatug vedotin | ADC | · | · | · | · | · | 0/7 | - | ||
| Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes) · Tacquell | TIL cell therapy (autologous tumour-infiltrating lymphocytes, ex vivo expanded) | · | 2026 | · | · | · | · | · | 0/7 | - |
| Tinengotinib | Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK) | · | · | · | · | · | 0/7 | - | ||
| Trastuzumab brengitecan | ADC | · | · | · | · | · | · | 0/7 | - | |
| Trastuzumab duocarmazine | ADC | 2023 | · | · | · | · | · | 0/7 | - | |
| Trilaciclib · Cosela | Intravenous CDK4/6 inhibitor given before chemotherapy to protect bone marrow | · | · | · | · | · | · | 0/7 | - | |
| Vorinostat · Zolinza | Small-molecule pan-HDAC inhibitor (hydroxamate) | · | · | · | · | · | · | 0/7 | - | |
| Xaluritamig | Bispecific T-cell engager (STEAP1×CD3, XmAb 2+1) | · | · | · | · | · | · | 0/7 | - | |
| Zilovertamab vedotin | ADC | · | · | · | · | · | · | 0/7 | - |
Years between the first approval anywhere and approval in each region, across products approved in that region. Zero means the region was among the first to approve.
| Region | Regulator | Approved | Median lag | Mean lag | First-in-world | Missing | Pending |
|---|---|---|---|---|---|---|---|
| United States | FDA | 291 | 0 yr | 0.4 yr | 249 | 115 | 42 |
| European Union | EMA / European Commission | 299 | 1 yr | 1.4 yr | 133 | 107 | 20 |
| United Kingdom | MHRA (NICE for reimbursement) | 240 | 1 yr | 1.6 yr | 66 | 166 | 6 |
| Japan | PMDA / MHLW | 197 | 3 yr | 3.2 yr | 29 | 209 | 5 |
| China | NMPA | 211 | 2 yr | 3.3 yr | 64 | 195 | 9 |
| Australia | TGA (PBS for reimbursement) | 189 | 1 yr | 2.1 yr | 15 | 217 | 6 |
| India | CDSCO (DCGI) | 9 | 0 yr | 0.0 yr | 3 | 397 | 0 |
Each cell is the regulator’s decision for the product in that region: the year of first oncology approval, a tick for full approval, ✓c for conditional or accelerated approval, … for a filing under review, a dash where the sponsor has said it will not file, and ✕ for a withdrawn or rejected application. A dot means we have no sourced record, which is not the same as “not approved”.
“First” is the earliest year of approval in any of the regions and the region(s) that granted it. Lag is measured in whole years against that first approval. “Missing” counts products approved somewhere but not in the region.
Regions: US = FDA, EU = EMA / European Commission, UK = MHRA (NICE for reimbursement), JP = PMDA / MHLW, CN = NMPA, AU = TGA (PBS for reimbursement), IN = CDSCO (DCGI). UK entries reflect MHRA marketing authorisation, not NICE reimbursement; Australian entries reflect TGA registration, not PBS listing; Indian entries reflect CDSCO approval or documented generic and biosimilar entry, and are recorded only where sourced.
US entries are seeded from the product corpus, which cites FDA approval notices. EU entries link to the EMA public assessment report; a small filled dot on a cell marks rows checked directly against the EPAR page. UK, Japan, China, Australia and India entries link to regulator search pages or company releases and are stated at year resolution only. Years for legacy chemotherapies predate online registers and are approximate.
This matrix is a work in progress. Approvals happen weekly, indications differ between regions even when a product is approved in both, and a missing cell most often means we have not yet sourced it. Verify at the regulator before relying on any cell. Corrections are welcome via the repo.